# Mosaic Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mosaic-biosciences

- Industry: Biotechnology
- Headquarters: Boulder, US
- Website: www.mosaicbio.com
- Total disclosed funding: $15M
- Latest round: Series A (Jun 14, 2022)
- Investors on record: 4

## About

Mosaic Biosciences, Inc. focuses on discovering and developing innovative protein therapeutics, particularly therapeutic antibodies, leveraging advanced technologies to enhance drug development success for biopharmaceutical clients.Founded in 2009 and headquartered in Boulder, US, Mosaic Biosciences, Inc. specializes in developing protein therapeutics. The company has undergone strategic growth with a recent funding round. Eric Furfine and Marty Stanton lead the company as CEOs. Mosaic has attracted significant investment, raising USD 11.4 mn in a Series A round on June 14, 2022, led by Telegraph Hill Partners, bringing total funds raised to USD 11.4 mn and current valuation to USD 25.529 mn.Mosaic Biosciences specializes in the discovery and development of protein therapeutics, focusing on therapeutic antibodies. Utilizing proprietary Phage and Yeast Display libraries, the company provides end-to-end discovery capabilities, from lead discovery to in vivo studies. Their clientele primarily includes global biopharmaceutical firms seeking to enhance drug pipelines, with engagement in key markets such as North America, Europe, and Asia.Mosaic Biosciences generates revenue through strategic partnerships and collaborations with biopharmaceutical companies. Clients contract the company's services for specific drug discovery and development phases, paying for access to their advanced technologies and scientific expertise. Revenue is derived from project milestones, including upfront payments for initial discovery and subsequent payments based on achieving clinical targets, ensuring necessary support during critical development stages.Following the USD 11.4 mn funding raised in June 2022, Mosaic Biosciences plans to expand its lab facility infrastructure and develop new technologies and capabilities. The growth strategy also includes increasing the business development team to enhance market presence. This funding will facilitate strategic expansions into new geographic regions and improve their service offerings.

## Funding rounds

- Series A, Jun 14, 2022, $11M — Telegraph Hill Partners
- Series A, Feb 11, 2014, $2.3M — HealthCare Ventures, Morgenthaler Ventures, High Country Venture
- Series A, Jul 20, 2011, $1M — HealthCare Ventures, Morgenthaler Ventures, High Country Venture

## Investors

- HealthCare Ventures — Series A
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series A
- High Country Venture (https://capitalatlas.ai/funds/high-country-venture) — Series A
- Telegraph Hill Partners (https://capitalatlas.ai/funds/telegraph-hill-partners) — Series A